Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gabapentin: in postherpetic neuralgia.

Monique P Curran1, Antona J Wagstaff

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|October 10, 2003
PubMed
Summary

Gabapentin effectively reduced pain and improved quality of life in adults with postherpetic neuralgia. This medication, a gamma-aminobutyric acid (GABA) analogue, demonstrated significant benefits over placebo in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Drugs & aging·2013
Same author

Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

Drugs & aging·2012
Same author

Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.

CNS drugs·2012
Same author

Live attenuated influenza vaccine (Fluenz™): a guide to its use in the prevention of seasonal influenza in children in the EU.

Paediatric drugs·2012
Same author

Crizotinib: in locally advanced or metastatic non-small cell lung cancer.

Drugs·2011
Same author

Canakinumab: in patients with cryopyrin-associated periodic syndromes.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2011

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Gabapentin is an analogue of gamma-aminobutyric acid (GABA).
  • It is approved for treating postherpetic neuralgia in adults.
  • Its precise mechanism of action in humans remains under investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of gabapentin in managing postherpetic neuralgia.
  • To compare gabapentin's effects against placebo in pain reduction and quality of life improvements.

Main Methods:

  • Two randomized, placebo-controlled trials were conducted.
  • Participants received daily dosages of gabapentin ranging from 1800 to 3600 mg.
  • Efficacy was assessed using daily pain scores, responder rates, sleep quality, and health surveys.

Main Results:

  • Gabapentin significantly reduced mean daily pain scores compared to placebo.
  • A greater proportion of patients receiving gabapentin achieved at least a 50% pain reduction.
  • Improvements were observed in sleep ratings, pain perception, and overall health status.

Conclusions:

  • Gabapentin is an effective treatment for postherpetic neuralgia, offering significant pain relief.
  • The drug demonstrated a favorable safety profile, with commonly reported side effects including dizziness and somnolence.
  • Gabapentin improves multiple aspects of health-related quality of life in patients with postherpetic neuralgia.

Related Experiment Videos